Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Revolution Medicines, Inc.RVMD · Entity 606 | Chief Operating Officer | September 16, 2026 | September 18, 2026 |
| SANGAMO THERAPEUTICS, INCSGMO · Entity 7038 | Director | June 12, 2025 | June 16, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Revolution Medicines, Inc.
Report date September 16, 2026 · Filed September 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 154,571 |
Reported balance
After 2026-09-16 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-16 · Sale · Disposed 76 · Balance 154,571 F1: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units. F2: The transaction was executed in multiple trades at prices ranging from $195.00 to $195.03, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |
| Common StockSEC Table I · non-derivative | Direct | 149,680 |
Reported balance
After 2026-09-16 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-09-16 · Sale · Disposed 4,891 · Balance 149,680 F1: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units. F3: Includes 56,713 restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units.
F2: The transaction was executed in multiple trades at prices ranging from $195.00 to $195.03, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F3: Includes 56,713 restricted stock units.
SANGAMO THERAPEUTICS, INC
Report date June 12, 2025 · Filed June 16, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 82,650 |
Reported balance
After 2025-06-12 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-06-12 · Grant · Acquired 25,000 · Balance 82,650 F1: Represents shares of common stock issuable upon settlement of a restricted stock unit ("RSU") grant that will fully vest on the earlier of (a) June 12, 2026 or (b) the day prior to the 2026 annual meeting of stockholders, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP")) through such date and subject to acceleration as provided in the 2018 EIP. F2: Includes 6,251 shares subject to the Reporting Person's December 15, 2022 RSU grant that will vest in one final installment on December 15, 2025. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.50 · Expires 2035-06-11 | Direct | 50,000 |
Reported balance
After 2025-06-12 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-06-12 · Grant · Acquired 50,000 · Balance 50,000 F3: The option is immediately exercisable in full, but any unvested shares that are purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's Continuous Service (as defined in the 2018 EIP). The shares subject to the option will vest in 12 successive equal monthly installments following the grant date, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock issuable upon settlement of a restricted stock unit ("RSU") grant that will fully vest on the earlier of (a) June 12, 2026 or (b) the day prior to the 2026 annual meeting of stockholders, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP")) through such date and subject to acceleration as provided in the 2018 EIP.
F2: Includes 6,251 shares subject to the Reporting Person's December 15, 2022 RSU grant that will vest in one final installment on December 15, 2025.
F3: The option is immediately exercisable in full, but any unvested shares that are purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's Continuous Service (as defined in the 2018 EIP). The shares subject to the option will vest in 12 successive equal monthly installments following the grant date, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 16, 2026 Filed Sep 18, 2026 22:03 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 4,891 | $199.30 | $974,791.95 |
DisclosureSEC source: 0001294192-26-000007 · ownership.xml · nonDerivative · entry 2 Horn Margaret A · CIK 0001294192 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 149,680 F1 · kind: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units. F3 · balance_after: Includes 56,713 restricted stock units. Read SEC document |
| September 16, 2026 Filed Sep 18, 2026 22:03 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 76 | $195.01 | $14,820.63 |
DisclosureSEC source: 0001294192-26-000007 · ownership.xml · nonDerivative · entry 1 Horn Margaret A · CIK 0001294192 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 154,571 F1 · kind: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units. F2 · price: The transaction was executed in multiple trades at prices ranging from $195.00 to $195.03, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| June 17, 2026 Filed Jun 17, 2026 23:51 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,725 | $0.00 Strike: $26.50 | $0.00 |
DisclosureSEC source: 0001610717-26-000230 · form4.xml · derivative · entry 13 Horn Margaret A · CIK 0001294192 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 114,275 Underlying: Common Stock · 25,725 shares Expires 2033-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 12, 2026. F10 · derivative.exercise_date: One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from March 1, 2023 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| June 17, 2026 Filed Jun 17, 2026 23:51 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,302 | $0.00 Strike: $29.80 | $0.00 |
DisclosureSEC source: 0001610717-26-000230 · form4.xml · derivative · entry 12 Horn Margaret A · CIK 0001294192 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 71,750 Underlying: Common Stock · 3,302 shares Expires 2034-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 12, 2026. F9 · derivative.exercise_date: One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from March 1, 2024 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| June 17, 2026 Filed Jun 17, 2026 23:51 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionStock Option (Right to Buy) · Derivative | 573 | $0.00 Strike: $40.74 | $0.00 |
DisclosureSEC source: 0001610717-26-000230 · form4.xml · derivative · entry 11 Horn Margaret A · CIK 0001294192 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 75,075 Underlying: Common Stock · 573 shares Expires 2035-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 12, 2026. F8 · derivative.exercise_date: One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from March 1, 2025 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| June 17, 2026 Filed Jun 17, 2026 23:51 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 29,600 | $160.12 | $4,739,679.28 |
DisclosureSEC source: 0001610717-26-000230 · form4.xml · nonDerivative · entry 8 Horn Margaret A · CIK 0001294192 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 154,647 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 12, 2026. F7 · price: This transaction was executed in multiple trades in prices ranging from $160.00 to $160.48, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F6 · balance_after: Includes 66,201 RSUs. Read SEC document |
| June 17, 2026 Filed Jun 17, 2026 23:51 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionCommon Stock | 25,725 | $26.50 | $681,712.50 |
DisclosureSEC source: 0001610717-26-000230 · form4.xml · nonDerivative · entry 7 Horn Margaret A · CIK 0001294192 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 184,247 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 12, 2026. F6 · balance_after: Includes 66,201 RSUs. Read SEC document |
| June 17, 2026 Filed Jun 17, 2026 23:51 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionCommon Stock | 3,302 | $29.80 | $98,399.60 |
DisclosureSEC source: 0001610717-26-000230 · form4.xml · nonDerivative · entry 6 Horn Margaret A · CIK 0001294192 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 158,522 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 12, 2026. F6 · balance_after: Includes 66,201 RSUs. Read SEC document |
| June 17, 2026 Filed Jun 17, 2026 23:51 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionCommon Stock | 573 | $40.74 | $23,344.02 |
DisclosureSEC source: 0001610717-26-000230 · form4.xml · nonDerivative · entry 5 Horn Margaret A · CIK 0001294192 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 155,220 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 12, 2026. F6 · balance_after: Includes 66,201 RSUs. Read SEC document |
| June 15, 2026 Filed Jun 17, 2026 23:51 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionStock Option (Right to Buy) · Derivative | 44,854 | $0.00 Strike: $29.80 | $0.00 |
DisclosureSEC source: 0001610717-26-000230 · form4.xml · derivative · entry 10 Horn Margaret A · CIK 0001294192 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 75,052 Underlying: Common Stock · 44,854 shares Expires 2034-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 12, 2026. F9 · derivative.exercise_date: One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from March 1, 2024 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| June 15, 2026 Filed Jun 17, 2026 23:51 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,546 | $0.00 Strike: $40.74 | $0.00 |
DisclosureSEC source: 0001610717-26-000230 · form4.xml · derivative · entry 9 Horn Margaret A · CIK 0001294192 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 75,648 Underlying: Common Stock · 15,546 shares Expires 2035-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 12, 2026. F8 · derivative.exercise_date: One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from March 1, 2025 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| June 15, 2026 Filed Jun 17, 2026 23:51 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 60,400 | $160.17 | $9,674,304.24 |
DisclosureSEC source: 0001610717-26-000230 · form4.xml · nonDerivative · entry 3 Horn Margaret A · CIK 0001294192 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 158,222 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 12, 2026. F3 · price: This transaction was executed in multiple trades in prices ranging from $160.00 to $160.3550, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 73,050 restricted stock units ("RSUs"). Read SEC document |
| June 15, 2026 Filed Jun 17, 2026 23:51 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionCommon Stock | 44,854 | $29.80 | $1,336,649.20 |
DisclosureSEC source: 0001610717-26-000230 · form4.xml · nonDerivative · entry 2 Horn Margaret A · CIK 0001294192 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 218,622 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 12, 2026. F2 · balance_after: Includes 73,050 restricted stock units ("RSUs"). Read SEC document |
| June 15, 2026 Filed Jun 17, 2026 23:51 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionCommon Stock | 15,546 | $40.74 | $633,344.04 |
DisclosureSEC source: 0001610717-26-000230 · form4.xml · nonDerivative · entry 1 Horn Margaret A · CIK 0001294192 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 173,768 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 12, 2026. F2 · balance_after: Includes 73,050 restricted stock units ("RSUs"). Read SEC document |
| June 11, 2026 Filed Jun 15, 2026 20:05 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,906 | $0.00 Strike: $40.74 | $0.00 |
DisclosureSEC source: 0001610717-26-000216 · form4.xml · derivative · entry 11 Horn Margaret A · CIK 0001294192 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 91,194 Underlying: Common Stock · 8,906 shares Expires 2035-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 12, 2026. F10 · derivative.exercise_date: One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from March 1, 2025 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| June 11, 2026 Filed Jun 15, 2026 20:05 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,094 | $0.00 Strike: $42.45 | $0.00 |
DisclosureSEC source: 0001610717-26-000216 · form4.xml · derivative · entry 10 Horn Margaret A · CIK 0001294192 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,094 shares Expires 2031-03-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 12, 2026. Read SEC document |
| June 11, 2026 Filed Jun 15, 2026 20:05 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 200 | $150.17 | $30,034.00 |
DisclosureSEC source: 0001610717-26-000216 · form4.xml · nonDerivative · entry 9 Horn Margaret A · CIK 0001294192 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 158,222 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 12, 2026. F2 · balance_after: Includes 73,050 restricted stock units. Read SEC document |
| June 11, 2026 Filed Jun 15, 2026 20:05 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 4,600 | $149.64 | $688,357.34 |
DisclosureSEC source: 0001610717-26-000216 · form4.xml · nonDerivative · entry 8 Horn Margaret A · CIK 0001294192 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 158,422 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 12, 2026. F9 · price: This transaction was executed in multiple trades in prices ranging from $149.17 to $150.15, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 73,050 restricted stock units. Read SEC document |
| June 11, 2026 Filed Jun 15, 2026 20:05 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 1,800 | $148.72 | $267,701.58 |
DisclosureSEC source: 0001610717-26-000216 · form4.xml · nonDerivative · entry 7 Horn Margaret A · CIK 0001294192 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 163,022 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 12, 2026. F8 · price: This transaction was executed in multiple trades in prices ranging from $148.14 to $149.08, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 73,050 restricted stock units. Read SEC document |
| June 11, 2026 Filed Jun 15, 2026 20:05 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 500 | $147.27 | $73,636.00 |
DisclosureSEC source: 0001610717-26-000216 · form4.xml · nonDerivative · entry 6 Horn Margaret A · CIK 0001294192 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 164,822 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 12, 2026. F7 · price: This transaction was executed in multiple trades in prices ranging from $147.06 to $147.41, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 73,050 restricted stock units. Read SEC document |
| June 11, 2026 Filed Jun 15, 2026 20:05 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 700 | $146.04 | $102,225.97 |
DisclosureSEC source: 0001610717-26-000216 · form4.xml · nonDerivative · entry 5 Horn Margaret A · CIK 0001294192 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 165,322 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 12, 2026. F6 · price: This transaction was executed in multiple trades in prices ranging from $145.88 to $146.16, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 73,050 restricted stock units. Read SEC document |
| June 11, 2026 Filed Jun 15, 2026 20:05 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 885 | $145.15 | $128,457.31 |
DisclosureSEC source: 0001610717-26-000216 · form4.xml · nonDerivative · entry 4 Horn Margaret A · CIK 0001294192 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 166,022 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 12, 2026. F5 · price: This transaction was executed in multiple trades in prices ranging from $144.79 to $145.61, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 73,050 restricted stock units. Read SEC document |
| June 11, 2026 Filed Jun 15, 2026 20:05 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 1,315 | $144.28 | $189,727.28 |
DisclosureSEC source: 0001610717-26-000216 · form4.xml · nonDerivative · entry 3 Horn Margaret A · CIK 0001294192 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 166,907 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 12, 2026. F4 · price: This transaction was executed in multiple trades in prices ranging from $143.78 to $144.76, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 73,050 restricted stock units. Read SEC document |
| June 11, 2026 Filed Jun 15, 2026 20:05 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionCommon Stock | 8,906 | $40.74 | $362,830.44 |
DisclosureSEC source: 0001610717-26-000216 · form4.xml · nonDerivative · entry 2 Horn Margaret A · CIK 0001294192 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 168,222 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 12, 2026. F2 · balance_after: Includes 73,050 restricted stock units. Read SEC document |
| June 11, 2026 Filed Jun 15, 2026 20:05 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionCommon Stock | 1,094 | $42.45 | $46,440.30 |
DisclosureSEC source: 0001610717-26-000216 · form4.xml · nonDerivative · entry 1 Horn Margaret A · CIK 0001294192 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 159,316 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 12, 2026. F2 · balance_after: Includes 73,050 restricted stock units. F3 · balance_after: Includes 652 shares acquired under the Issuer's Employee Stock Purchase Plan on May 31, 2026. Read SEC document |
| March 17, 2026 Filed Mar 19, 2026 22:56 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 4,583 | $99.48 | $455,918.67 |
DisclosureSEC source: 0001610717-26-000129 · form4.xml · nonDerivative · entry 1 Horn Margaret A · CIK 0001294192 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 157,570 F1 · kind: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs") after July 15, 2023. F2 · balance_after: Includes 73,050 RSUs. Read SEC document |
| March 01, 2026 Filed Mar 4, 2026 02:08 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | GrantStock Option (Right to Buy) · Derivative | 47,600 | $0.00 Strike: $102.02 | $0.00 |
DisclosureSEC source: 0001610717-26-000081 · form4.xml · derivative · entry 2 Horn Margaret A · CIK 0001294192 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,600 Underlying: Common Stock · 47,600 shares Expires 2036-02-28 F2 · derivative.exercise_date: One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from March 1, 2026 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| March 01, 2026 Filed Mar 4, 2026 02:08 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | GrantCommon Stock | 21,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-26-000081 · form4.xml · nonDerivative · entry 1 Horn Margaret A · CIK 0001294192 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 162,153 F1 · balance_after: Includes 82,326 restricted stock units. Read SEC document |
| January 07, 2026 Filed Jan 9, 2026 21:20 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionStock Option (Right to Buy) · Derivative | 23,594 | $0.00 Strike: $29.80 | $0.00 |
DisclosureSEC source: 0001610717-26-000013 · form4.xml · derivative · entry 7 Horn Margaret A · CIK 0001294192 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 119,906 Underlying: Common Stock · 23,594 shares Expires 2034-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 7, 2025. F5 · derivative.exercise_date: One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from March 1, 2024 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| January 07, 2026 Filed Jan 9, 2026 21:20 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionStock Option (Right to Buy) · Derivative | 51,406 | $0.00 Strike: $42.45 | $0.00 |
DisclosureSEC source: 0001610717-26-000013 · form4.xml · derivative · entry 6 Horn Margaret A · CIK 0001294192 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,094 Underlying: Common Stock · 51,406 shares Expires 2031-03-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 7, 2025. Read SEC document |
| January 07, 2026 Filed Jan 9, 2026 21:20 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 1,700 | $102.90 | $174,930.00 |
DisclosureSEC source: 0001610717-26-000013 · form4.xml · nonDerivative · entry 5 Horn Margaret A · CIK 0001294192 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 141,053 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 7, 2025. F2 · balance_after: Includes 61,226 restricted stock units. Read SEC document |
| January 07, 2026 Filed Jan 9, 2026 21:20 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 20,204 | $101.79 | $2,056,621.73 |
DisclosureSEC source: 0001610717-26-000013 · form4.xml · nonDerivative · entry 4 Horn Margaret A · CIK 0001294192 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 142,753 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 7, 2025. F4 · price: This transaction was executed in multiple trades in prices ranging from $101.07 to $101.96, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 61,226 restricted stock units. Read SEC document |
| January 07, 2026 Filed Jan 9, 2026 21:20 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 53,096 | $100.02 | $5,310,470.77 |
DisclosureSEC source: 0001610717-26-000013 · form4.xml · nonDerivative · entry 3 Horn Margaret A · CIK 0001294192 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 162,957 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 7, 2025. F3 · price: This transaction was executed in multiple trades in prices ranging from $100.00 to $100.19, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 61,226 restricted stock units. Read SEC document |
| January 07, 2026 Filed Jan 9, 2026 21:20 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionCommon Stock | 23,594 | $29.80 | $703,101.20 |
DisclosureSEC source: 0001610717-26-000013 · form4.xml · nonDerivative · entry 2 Horn Margaret A · CIK 0001294192 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 216,053 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 7, 2025. F2 · balance_after: Includes 61,226 restricted stock units. Read SEC document |
| January 07, 2026 Filed Jan 9, 2026 21:20 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionCommon Stock | 51,406 | $42.45 | $2,182,184.70 |
DisclosureSEC source: 0001610717-26-000013 · form4.xml · nonDerivative · entry 1 Horn Margaret A · CIK 0001294192 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 192,459 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 7, 2025. F2 · balance_after: Includes 61,226 restricted stock units. Read SEC document |
| December 16, 2025 Filed Dec 18, 2025 21:16 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 4,847 | $76.82 | $372,333.45 |
DisclosureSEC source: 0001610717-25-000421 · form4.xml · nonDerivative · entry 1 Horn Margaret A · CIK 0001294192 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 141,053 F1 · kind: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs") after July 15, 2023. F2 · balance_after: Includes 61,226 restricted stock units. Read SEC document |
| September 16, 2025 Filed Sep 18, 2025 20:36 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 4,775 | $45.82 | $218,813.90 |
DisclosureSEC source: 0001610717-25-000348 · form4.xml · nonDerivative · entry 1 Horn Margaret A · CIK 0001294192 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 145,900 F1 · kind: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs") after July 15, 2023. F2 · balance_after: Includes 70,500 restricted stock units. Read SEC document |
| June 16, 2025 Filed Jun 18, 2025 20:06 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 3,510 | $39.83 | $139,803.30 |
DisclosureSEC source: 0001610717-25-000242 · form4.xml · nonDerivative · entry 1 Horn Margaret A · CIK 0001294192 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 150,675 F1 · kind: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs") after July 15, 2023. F2 · price: This transaction was executed in multiple trades in prices ranging from $39.6017 to $39.8291, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · balance_after: Includes 652 shares acquired under the Issuer's Employee Stock Purchase Plan on May 31, 2025. F4 · balance_after: Includes 79,776 RSUs. Read SEC document |
| June 16, 2025 Filed Jun 17, 2026 23:51 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 3,575 | $156.12 | $558,126.50 |
DisclosureSEC source: 0001610717-26-000230 · form4.xml · nonDerivative · entry 4 Horn Margaret A · CIK 0001294192 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 154,647 F4 · kind: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of RSUs after July 15, 2023. F5 · price: This transaction was executed in multiple trades in prices ranging from $156.1105 to $156.8250, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F6 · balance_after: Includes 66,201 RSUs. Read SEC document |
| June 12, 2025 Filed Jun 16, 2025 20:05 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $0.50 | $0.00 |
DisclosureSEC source: 0001415889-25-017370 · form4-06162025_040607.xml · derivative · entry 2 Horn Margaret A · CIK 0001294192 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2035-06-11 F3 · derivative.exercise_date: The option is immediately exercisable in full, but any unvested shares that are purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's Continuous Service (as defined in the 2018 EIP). The shares subject to the option will vest in 12 successive equal monthly installments following the grant date, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document |
| June 12, 2025 Filed Jun 16, 2025 20:05 UTC | SANGAMO THERAPEUTICS, INC SGMO · Entity 7038 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-017370 · form4-06162025_040607.xml · nonDerivative · entry 1 Horn Margaret A · CIK 0001294192 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,650 F1 · shares: Represents shares of common stock issuable upon settlement of a restricted stock unit ("RSU") grant that will fully vest on the earlier of (a) June 12, 2026 or (b) the day prior to the 2026 annual meeting of stockholders, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP")) through such date and subject to acceleration as provided in the 2018 EIP. F2 · balance_after: Includes 6,251 shares subject to the Reporting Person's December 15, 2022 RSU grant that will vest in one final installment on December 15, 2025. Read SEC document |
| March 17, 2025 Filed Mar 19, 2025 21:41 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 3,058 | $39.04 | $119,385.24 |
DisclosureSEC source: 0001610717-25-000078 · form4.xml · nonDerivative · entry 1 Horn Margaret A · CIK 0001294192 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 153,533 F1 · kind: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs") after July 15, 2023. F2 · balance_after: Includes 89,050 RSUs. Read SEC document |
| March 01, 2025 Filed Mar 5, 2025 00:02 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | GrantStock Option (Right to Buy) · Derivative | 100,100 | $0.00 Strike: $40.74 | $0.00 |
DisclosureSEC source: 0001610717-25-000053 · form4.xml · derivative · entry 2 Horn Margaret A · CIK 0001294192 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,100 Underlying: Common Stock · 100,100 shares Expires 2035-02-28 F2 · derivative.exercise_date: One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from March 1, 2025 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| March 01, 2025 Filed Mar 5, 2025 00:02 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | GrantCommon Stock | 28,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-25-000053 · form4.xml · nonDerivative · entry 1 Horn Margaret A · CIK 0001294192 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 156,591 F1 · balance_after: Includes 97,476 restricted stock units. Read SEC document |
| December 16, 2024 Filed Dec 18, 2024 21:09 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 4,329 | $45.40 | $196,553.05 |
DisclosureSEC source: 0001610717-24-000547 · form4.xml · nonDerivative · entry 1 Horn Margaret A · CIK 0001294192 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 127,991 F1 · kind: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs") after July 15, 2023. F2 · balance_after: Includes 68,876 RSUs. Read SEC document |
| October 11, 2024 Filed Oct 15, 2024 21:31 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,369 | $0.00 Strike: $4.09 | $0.00 |
DisclosureSEC source: 0001610717-24-000509 · form4.xml · derivative · entry 5 Horn Margaret A · CIK 0001294192 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 97,382 Underlying: Common Stock · 5,369 shares Expires 2029-03-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 22, 2024. Read SEC document |
| October 11, 2024 Filed Oct 15, 2024 21:31 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionStock Option (Right to Buy) · Derivative | 44,631 | $0.00 Strike: $4.09 | $0.00 |
DisclosureSEC source: 0001610717-24-000509 · form4.xml · derivative · entry 4 Horn Margaret A · CIK 0001294192 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 44,631 shares Expires 2029-03-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 22, 2024. Read SEC document |
| October 11, 2024 Filed Oct 15, 2024 21:31 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 50,000 | $50.34 | $2,517,055.00 |
DisclosureSEC source: 0001610717-24-000509 · form4.xml · nonDerivative · entry 3 Horn Margaret A · CIK 0001294192 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 132,320 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 22, 2024. F3 · price: This transaction was executed in multiple trades in prices ranging from $50.00 to $50.82, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 77,300 restricted stock units. Read SEC document |
| October 11, 2024 Filed Oct 15, 2024 21:31 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionCommon Stock | 5,369 | $4.09 | $21,959.21 |
DisclosureSEC source: 0001610717-24-000509 · form4.xml · nonDerivative · entry 2 Horn Margaret A · CIK 0001294192 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 182,320 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 22, 2024. F2 · balance_after: Includes 77,300 restricted stock units. Read SEC document |
| October 11, 2024 Filed Oct 15, 2024 21:31 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | Exercise / conversionCommon Stock | 44,631 | $4.09 | $182,540.79 |
DisclosureSEC source: 0001610717-24-000509 · form4.xml · nonDerivative · entry 1 Horn Margaret A · CIK 0001294192 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 176,951 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 22, 2024. F2 · balance_after: Includes 77,300 restricted stock units. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.